Zimbabwe has declined a substantial American health deal valued at $367m (272 million pounds) spanning five years over the United States' insistence on confidential information.
This rejection was revealed following a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa believed the deal was "skewed".
An official spokesman has since stated that the US was demanding access to biological samples for scientific study and profit while was not willing to share the benefits from future medical innovations.
"We are forced to start the difficult and regrettable process of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further talks to secure a deal suitable to both sides so the country's critical HIV treatment initiative can continue.
Wider Background
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court blocked a related health funding agreement after legal challenges were filed about the security of Kenyans' health data.
After resuming office last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had managed aid for the American government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral deals to boost transparency and accountability.
As per reports, 16 nations in Africa have so far signed these new health pacts, representing more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered immense advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, with no corresponding assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the raw materials for medical research with no assurance that the end products would be accessible to our people if a future pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the global health body and its pursuit of one-on-one deals were undermining structures previously set up through the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This framework is designed to guarantee that when a nation provides its samples, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome further discussions with our US partners on how subsequent collaboration could be designed in a manner that honours the sovereignty and dignity of each country."
Medical Community Reaction
A leading public health body said it understood the government's concerns, but urged that negotiations need to persist given that much of the country's HIV programmes were funded by international support.
"In cases where technical issues arise, including those involving data governance or implementation frameworks, these can often be addressed through technical clarification and negotiated safeguards," it said.
The situation highlights the ongoing challenges between accepting much-needed foreign assistance and protecting national sovereignty in an increasingly data-driven world.